logo
Cardiac Arrest Survival Rises Over Last Two Decades

Cardiac Arrest Survival Rises Over Last Two Decades

Medscape22-07-2025
TOPLINE:
While the incidence of cardiac arrest occurring outside the hospital has remained relatively stable, at about 81 per 100,000 person-years, between 2001 and 2020, data show survival rates improved from 14.7% to 18.9% during that period. This improvement corresponded with increased bystander cardiopulmonary resuscitation (CPR), from 55.5% to 73.9%, and the use of early automated external defibrillators, from 2.2% to 10.9%.
METHODOLOGY:
Researchers conducted a retrospective cohort analysis of 25,118 adults in King County, Washington, who had experienced an out-of-hospital cardiac arrest (OHCA) treated by emergency medical services (EMS) between 2001 and 2020.
Of those, 15,994 (63.7%) were men and 9124 were women; the median age was 65 years.
Annual incidence calculations were stratified by sex, age group (less than 65 years and 65 years or older), and initial rhythm (shockable, nonshockable).
The tesearchers evaluated temporal trends using Poisson regression for incidence and survival to hospital discharge, with resuscitation assessed in five-year groups.
TAKEAWAY:
Overall survival to hospital discharge improved significantly over time: 14.7% (859 of 5847 individuals) in 2001-2005, 17.4% (1024 of 5885 individuals) in 2006-2010, 19.3% (1232 of 6376 individuals) in 2011-2015, and 18.9% (1322 of 7010 individuals) in 2016-2020 (P < .001 for trend).
Survival rates increased substantially for shockable OHCA, from 35% to 47.5%, and for nonshockable OHCA, from 6.4% to 10.1% between the periods spanning 2001-2005 and 2016-2020 (P < .001 for trend).
Improvements were observed in both prehospital resuscitation (survival to hospital admission) and in-hospital survival (P < .001 for trend).
Community response rose significantly, with bystander CPR increasing from 55.5% to 73.9% and early use of an automated external defibrillator rising from 2.2% to 10.9% (P < .001 for trend).
IN PRACTICE:
'Resuscitation outcomes improved over time, a temporal trend that was evident overall and when stratified by presenting arrest rhythm,' the researchers reported. 'The outcome improvements corresponded to improvements in health services such as increase in bystander CPR, AED application before EMS among patients with shockable rhythm, and hospital-based care with targeted temperature management and coronary intervention. The results demonstrate the dynamic nature of OHCA incidence and resuscitation care and outcome that collectively help provide a foundational context to consider strategies of prevention and treatment.'
SOURCE:
The study was led by Owen McBride, MD, of the Department of Emergency Medicine at the University of Washington in Seattle. It was published online July 16 in JAMA Cardiology.
LIMITATIONS:
According to the authors, while the study represents a singular regional experience that could affect generalizability, as OHCA incidence and outcome can vary based on geography. Some people who experience OHCA have an emergency response but do not receive resuscitation attempts due to signs of irreversible death or do-not-resuscitate orders, whereas some OHCA events do not receive a 911 medical response.
DISCLOSURES:
Michael Sayre, MD, reported receiving personal fees from Styker Emergency Response outside the submitted work. Thomas Rea, MD, MPH, reported receiving grants from Philips Medical Funding and the American Heart Association for research independent of the current publication. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

Yahoo

time3 hours ago

  • Yahoo

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Yahoo

time3 hours ago

  • Yahoo

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away
Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away

Forbes

time3 hours ago

  • Forbes

Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away

A man walks his dog past a homeless man sleeping under a message painted on a boarded up shop in San ... More Francisco, California on April, 1, 2020, during the novel coronavirus outbreak. - The US death toll from the coronavirus pandemic topped 5,000 late on April 1, according to a running tally from Johns Hopkins University. (Photo by Josh Edelson / AFP) (Photo by JOSH EDELSON/AFP via Getty Images) For decades, every administration, every Congress, put many things off for someone else to deal with. No one can get everything done all the time, that's understandable. But many current economic and social programs aren't a result of juggling what might be possible. Instead, they have become the ultimate attempt to kick every can down the road. That doesn't solve problems. It only hides them and allows them to grow and fester. One of the current examples is homelessness. Here is a statement out of the presidential executive order, Ending Crime And Disorder On America's Streets: 'The overwhelming majority of these individuals are addicted to drugs, have a mental health condition, or both. Nearly two-thirds of homeless individuals report having regularly used hard drugs like methamphetamines, cocaine, or opioids in their lifetimes. An equally large share of homeless individuals reported suffering from mental health conditions.' Homelessness is a problem in many parts of the country. And, yes, people on the streets are often troubled in one way or another. However, the entire executive order is a rhetorical setup, claiming that 'nearly two-thirds' of the individuals reporting having used 'hard drugs like methamphetamines, cocaine, or opioids in their lifetimes.' No source for the statistic that is then delivered to deemphasize that any such use might have been long before. And then a statement that an 'equally large share of homeless individuals reported suffering from mental health conditions.' No source, again, and no explanation of what mental health conditions mean. Broadly defined enough, like any amount of depression, anxiety, discomfort, and so on, it could include everyone in the country. Next, a combination of claiming that spending by the federal government and states has run tens of billions on failed programs 'that address homelessness but not its root causes.' After claiming that homeless people leave 'other citizens vulnerable to public safety threats' comes the statement, 'Shifting homeless individuals into long-term institutional settings for humane treatment through the appropriate use of civil commitment will restore public order.' After stating that previous spending never looked at root causes, presuming that the administration knows the root causes, the proffered solution is to lock people away. The message is to ignore the problem and put it out of sight. The point isn't really for safety, because most dangerous behavior in the country doesn't come from homeless people. It's for comfort and to pretend everything is fine. This has economic and social implications. Institutionalize where? Privately owned prisons where someone makes a lot of money from incarcerations? Hospitals that have been financially struggling but will even more now that Medicaid has been so thoroughly cut? Similar issues come in arguments over diversity, equity, and inclusion, or DEI. The administration wants it purged not only from websites and government discussions, but from corporations, universities, and anywhere else the term might appear. Again, the communication expressed by action is to strike any mention of the topic anywhere, to bury it from consciousness as though that makes issues go away. It never does. Other parts of life are no different. Corporations want to promote the use of the most recent forms of artificial intelligence. Traditionally, the argument executives would use is not that technology was about enabling job cuts, but to free people up to do more useful and interesting work. That mask has finally begun to slip as CEOs and their corporations boast of shrinking their workforces. Ultimately, this will lead to fewer people being employed, greater degrees of consumer financial struggle, and economic weakness. But, again, that all gets brushed under the carpet. No society can long stand with such undermining. So long as problems are ignored, they likely grow worse until there comes a point that they demand more resources than are available.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store